Advertisement
PBE vs XBI
Which ETF would AI Choose? Invesco Biotechnology & Genome ETF (PBE) vs. SPDR S&P Biotech ETF (XBI)
Key Takeaways
- Invesco Biotechnology & Genome ETF (PBE) employs a multi-factor Intellidex strategy selecting approximately 30 holdings with quarterly rebalancing, while SPDR S&P Biotech ETF (XBI) uses an equal-weighted approach across roughly 165 holdings for broader exposure.
- PBE concentrates on companies benefiting from biotechnology and genetic engineering advances with top positions often exceeding 5% weight, whereas XBI distributes risk more evenly with individual holdings typically under 3%.
- XBI offers a lower expense ratio of 0.35% compared to PBE’s 0.59%, potentially improving net returns for cost-sensitive investors over time.
- Both ETFs provide targeted U.S. biotechnology sector exposure but differ in risk profiles: PBE’s concentrated, rules-based selection may amplify volatility from key holdings, while XBI’s equal weighting emphasizes small- and mid-cap names.
- Structural differences position PBE as a thematic, momentum-driven vehicle and XBI as a diversified industry benchmark tracker within the same healthcare subsector.
Introduction
Investors seeking biotechnology exposure often compare Invesco Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI) because both target the same dynamic sector yet follow distinct methodologies. These funds do not compete directly but offer alternative strategies for capturing growth from drug development, genomics, and related innovations. PBE applies quantitative screens for momentum and quality, while XBI delivers modified equal-weighted representation of the broader biotechnology industry. The comparison helps clarify trade-offs in concentration, cost, and diversification for portfolio construction in the current environment of evolving healthcare innovation and regulatory scrutiny.
Invesco Biotechnology & Genome ETF (PBE) Overview
Invesco Biotechnology & Genome ETF (PBE) seeks to track the Dynamic Biotech & Genome Intellidex Index, which evaluates U.S. biotechnology and genome companies using criteria including price momentum, earnings momentum, quality, management action, and value. The fund maintains approximately 30 to 32 holdings and reconstitutes quarterly. Top positions as of recent data include Illumina Inc. (ILMN), Natera Inc. (NTRA), Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD), and Amgen Inc. (AMGN), each typically weighted between 4% and 6%. The portfolio is nearly 100% allocated to healthcare, primarily biotechnology. Its expense ratio stands at 0.59%. The strategy represents a rules-based, non-diversified approach designed for capital appreciation through multi-factor selection rather than pure market-cap weighting.
SPDR S&P Biotech ETF (XBI) Overview
SPDR S&P Biotech ETF (XBI) aims to track the S&P Biotechnology Select Industry Index, which captures the biotechnology segment of the S&P Total Market Index through modified equal weighting. The fund holds approximately 160 to 165 securities and rebalances quarterly. Individual holdings generally range from 1% to 2.5%, with recent top names including Moderna Inc. (MRNA), Natera Inc. (NTRA), Twist Bioscience Corp. (TWST), and Amgen Inc. (AMGN). Exposure remains overwhelmingly in healthcare biotechnology. The expense ratio is 0.35%. This passive structure provides broad industry representation with reduced single-name concentration, emphasizing smaller-capitalization companies alongside larger peers.
Industry and Thematic Backdrop
The biotechnology sector continues to benefit from advances in gene editing, personalized medicine, and novel therapeutics, supported by ongoing research pipelines and potential regulatory approvals. Macroeconomic factors such as interest rate expectations influence capital availability for research-intensive firms, while policy developments around drug pricing and intellectual property remain key variables. Capital flows into healthcare innovation have shown resilience across recent market cycles, though sector volatility persists due to clinical trial outcomes and competitive pressures. Both ETFs operate within this environment, where scientific breakthroughs can drive long-term growth alongside risks from development failures and reimbursement challenges.
Performance and Positioning Comparison
Over recent weeks and months, the funds have reflected broader biotechnology sector rotation driven by earnings reports from leading companies and shifting sentiment around innovation pipelines. PBE’s concentrated holdings can lead to sharper moves tied to specific catalysts in its top names, while XBI’s equal weighting tends to moderate extreme swings through broader participation across market-capitalization tiers. In recent market cycles, XBI’s lower cost structure and diversified profile have positioned it for steadier exposure during periods of sector-wide momentum, whereas PBE’s multi-factor methodology may capture outperformance from selected high-momentum securities. Relative positioning highlights trade-offs between targeted selection and comprehensive industry coverage amid evolving macroeconomic conditions.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into funds like Invesco Biotechnology & Genome ETF (PBE) or SPDR S&P Biotech ETF (XBI) may find the platform useful for refining their research process.
Tickeron AI Verdict
Based on structural strength, cost efficiency, and diversification profile, Tickeron’s AI would currently assign a higher probability of favor to SPDR S&P Biotech ETF (XBI). Its lower expense ratio, broader holding count, and equal-weighted methodology provide more consistent sector representation with reduced concentration risk compared to the more selective, higher-cost approach of Invesco Biotechnology & Genome ETF (PBE). Trend consistency and risk exposure metrics further support this probabilistic assessment within the biotechnology thematic space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBE is a Buy and XBI is a Hold.
Momentum Indicator for PBE turns positive, indicating new upward trend
PBE saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 84 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PBE just turned positive on October 15, 2026. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
PBE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PBE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in 258 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 218 of 254 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
PBE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
XBI's Stochastic Oscillator climbs into overbought zone
The Stochastic Oscillator for XBI moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
XBI moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XBI as a result. In 86 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for XBI just turned positive on October 21, 2026. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in 52 of 55 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 296 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
| PBE | XBI | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 90% |
| Declines ODDS (%) | 10 days ago 79% | 1 day ago 89% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 90% |
Advertisement
PBE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PBE has been loosely correlated with NTLA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PBE jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To PBE | 1D Price Change % | ||
|---|---|---|---|---|
| PBE | 100% | -0.18% | ||
| NTLA - PBE | 64% Loosely correlated | -4.21% | ||
| RGNX - PBE | 61% Loosely correlated | N/A | ||
| AVXL - PBE | 52% Loosely correlated | N/A | ||
| PRTA - PBE | 50% Loosely correlated | +2.74% | ||
| PGEN - PBE | 50% Loosely correlated | -3.18% | ||
More | ||||
XBI and
Correlation & Price change
A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -0.75% | ||
| RCUS - XBI | 60% Loosely correlated | +1.36% | ||
| VYGR - XBI | 59% Loosely correlated | -7.92% | ||
| LYEL - XBI | 57% Loosely correlated | -0.32% | ||
| LGND - XBI | 56% Loosely correlated | -2.21% | ||
| MGNX - XBI | 55% Loosely correlated | +1.11% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPSK | 17.50 | N/A | N/A |
| SP Funds Dow Jones Global Sukuk ETF (SPSK) | |||
| IPAV | 29.74 | N/A | N/A |
| Global X Infrastructure Development ex-U.S. ETF (IPAV) | |||
| SECT | 70.94 | -0.91 | -1.27% |
| Main Sector Rotation ETF (SECT) | |||
| ONOF | 40.80 | -0.59 | -1.42% |
| Global X Adaptive U.S. Risk Management ETF (ONOF) | |||
| MARS | 21.91 | -1.24 | -5.36% |
| Roundhill Space & Technology ETF (MARS) | |||